Feb 13, 2023

Featuring an interview with Dr Edward Garon, including the following topics:

• Treatment of non-small cell lung cancer (NSCLC) today versus prior to the availability of immune checkpoint inhibitors (0:00)
• Current and emerging roles of antibody-drug conjugates in NSCLC (3:30)
• Optimal workup for patients presenting with metastatic NSCLC; role of biomarker assessment (5:02)
• Considerations for the addition of an anti-CTLA-4 antibody to the treatment regimen for NSCLC (17:30)
• Correlation between immune-related toxicity and the efficacy of immune checkpoint inhibitors (21:47)
• Case: A woman in her mid 60s with multiple comorbidities presenting with NSCLC with a KRAS G12A mutation, pleural effusion and extensive bone metastases (24:35)
• Case: A man in his mid 50s with a long smoking history presenting with squamous cell carcinoma of the lung (31:07)
• Case: A woman in her early 60s with NSCLC with an EGFR L858R mutation who is relapsing after treatment with multiple therapies (37:22)
• Language barriers leading to disparities in clinical trial enrollment (44:38)

CME information and select publications